Abstract
Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Current Pharmaceutical Analysis
Title:Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method
Volume: 10 Issue: 4
Author(s): Caren Gobetti, Rubia Lazzaretti Pereira, Andreas Sebastian Loureiro Mendez and Cássia Virginia Garcia
Affiliation:
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Abstract: Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Export Options
About this article
Cite this article as:
Gobetti Caren, Pereira Lazzaretti Rubia, Mendez Sebastian Loureiro Andreas and Garcia Virginia Cássia, Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140610211656
DOI https://dx.doi.org/10.2174/1573412910666140610211656 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chlamydial Heat Shock Protein 60 and Lipopolysaccharide: Potential Virulence Determinants in Atherogenesis
Current Drug Targets - Inflammation & Allergy Progress of Stem Cell Transplantation for Treating Myocardial Infarction
Current Stem Cell Research & Therapy Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer’s Disease
Current Alzheimer Research Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Combined Bazedoxifene and Genistein Ameliorate Ovariectomy-Induced Hippocampal Neuro-Alterations via Activating CREB/BDNF/TrkB Signaling Pathway
Current Molecular Pharmacology Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs
Current Pharmaceutical Design Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
Current Cardiology Reviews Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review
Current Hypertension Reviews Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms
Current Hypertension Reviews Spastin Interacts with CRMP2 to Regulate Neurite Outgrowth by Controlling Microtubule Dynamics through Phosphorylation Modifications
CNS & Neurological Disorders - Drug Targets Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
Current Medicinal Chemistry Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity
Current Alzheimer Research Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry How Do Microbubbles and Ultrasound Interact? Basic Physical, Dynamic and Engineering Principles
Current Pharmaceutical Design